GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of
GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days
to Participants With Probable Alzheimer's Disease